Kaleido Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing Microbiome Metabolic Therapies™ (MMTs) that leverage the human microbiome to address diseases with significant unmet medical needs. The company’s proprietary platform uses synthetic glycans to modulate microbial metabolism and host–microbiome interactions. By focusing on small-molecule glycans rather than live bacteria or complex fecal transplants, Kaleido aims to deliver controlled and reproducible therapies designed for safety, stability, and oral dosing convenience.
The company’s pipeline features several MMT candidates in various stages of development targeting gastrointestinal, metabolic, and rare diseases. Lead programs include therapies for inflammatory bowel disease, irritable bowel syndrome, and urea cycle disorders, among others. Kaleido’s discovery engine enables rapid design and screening of novel glycan molecules, and the company has established strategic collaborations with leading academic centers and industry partners to accelerate clinical and regulatory progress.
Founded in 2015 by Flagship Pioneering, Kaleido is headquartered in Lexington, Massachusetts, and conducts clinical trials across North America and Europe. Under the leadership of President and Chief Executive Officer Brett D. Baird, Pharm.D., the company has built a multidisciplinary team with deep expertise in microbiology, chemistry, and translational medicine. With a focus on innovation and scientific rigor, Kaleido Biosciences is advancing its MMT platform to deliver new treatment options that harness the therapeutic potential of the microbiome.
AI Generated. May Contain Errors.
